LUND, Sweden, Oct. 12, 2022 /PRNewswire/ -- Immunovia AB
(Nasdaq Stockholm: IMMNOV) today announced positive feedback from
its physician experience program for the IMMray™ PanCan-d test in
the U.S., which is nearing completion. The program has included 23
high risk surveillance centers around the U.S. thus far, and
physicians have showed substantial interest in the use of IMMray™
PanCan-d to detect early-stage pancreatic cancer.
Immunovia's physician experience program was designed for
providers in the U.S. to gain clinical experience using the IMMray™
PanCan-d test. Feedback from participating physicians suggests
IMMray™ PanCan-d is an important test for early detection of
Pancreatic Cancer and their centers would like to incorporate the
test into regular patient care. The novel test has been broadly
adopted by physicians at the 23 high risk surveillance centers
across the US and has contributed to more patients getting screened
for early-stage pancreatic cancer. The company anticipates the
completion of the initial physician experience program to occur
before the end of the year. Upon completion, the company intends to
release a more comprehensive analysis of feedback and usage trends
among initial participants.
Dr. Rosario Ligresti from
Hackensack Meridian Health's New
Jersey surveillance center has used the IMMray™ PanCan-d
test since April. According to Dr. Ligresti being able to offer a
blood test that can detect early-stage pancreatic ductal
adenocarcinoma (PDAC) is a game-changer.
He said, "With our location in New
Jersey, and with the number of high-quality surveillance
programs around us, IMMray™ PanCan-d is a marketing tool to draw
new patients into our surveillance program. The current imaging
modalities are imperfect and not always pleasant for our patients.
Beyond that, IMMray™ PanCan-d has been a great adjunct to our
surveillance program, providing additional information to help us
better manage our patients."
In September, Immunovia received a preliminary determination
rate for IMMray™ PanCan-d from The Centers of Medicare &
Medicaid Services.
"We are very pleased with the positive feedback on our physician
experience program in the U.S.," said Philipp Mathieu – CEO and President of
Immunovia. "Increasing the number of patients that get diagnosed in
the early-stage pancreatic cancer makes it possible for more
patients to have surgical resection of their tumor, which today is
the only potentially curative treatment available for PDAC. The
recent preliminary determination rate from CMS and our successful
physician experience program are important steps in building
Immunovia's commercial presence in the U.S."
For more information, please contact:
Philipp Mathieu
CEO and President
philipp.mathieu@immunovia.com
Karin Almqvist Liwendahl
Chief Financial Officer
karin.almqvist.liwendahl@immunovia.com
About Immunovia
Immunovia AB is a diagnostic company with the vision to
revolutionize blood-based diagnostics and increase survival rates
for patients with cancer.
Our first product, IMMray™ PanCan-d is the only blood test
currently available for early detection of pancreatic cancer. The
test has unmatched clinical performance. Commercialization of
IMMray™ PanCan-d started in August
2021 in the USA and IMMray™
PanCan-d is offered as a laboratory developed test (LDT)
exclusively through Immunovia, Inc. For more information
see: www.immunoviainc.com.
Immunovia collaborates and engages with healthcare providers,
leading experts and patient advocacy groups globally to make this
test available to all high-risk pancreatic cancer groups.
The USA, the first market in
which IMMray™ PanCan-d is commercially available, is the world's
largest market for the detection of pancreatic cancer with an
estimated value of more than USD 4
billion annually.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit https://immunovia.com/
The following files are available for download:
https://mb.cision.com/Main/13121/3646780/1637539.pdf
|
Press release
(PDF)
|
View original
content:https://www.prnewswire.co.uk/news-releases/immunovia-announces-positive-update-on-physician-experience-program-with-immray-pancan-d-301646901.html